Latest Bladder Data Keep Roche's Atezolizumab In Contention
This article was originally published in Scrip
Executive Summary
Longer-term data from Roche's pivotal Phase II IMvigor 210 study of its anti-PD-L1 product atezolizumab looks set to bolster its position in the bladder cancer market as it seeks to catch up with frontrunners Opdivo and Keytruda in lung cancer.